Jun Qi

List of Publications by Citations

114	12,755	40	112
papers	citations	h-index	g-index
120	15,292	14.6	5.52
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
114	Selective inhibition of BET bromodomains. *Nature*, **2010**, 468, 1067-73	50.4	2725
113	BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell*, **2011**, 146, 904-17	56.2	2045
112	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature*, **2011**, 478, 524-8	50.4	1398
111	Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. *Cancer Cell*, **2013**, 24, 777-90	24.3	491
110	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/mA/MYC/CEBPA Signaling. *Cell*, **2018**, 172, 90-105.e23	56.2	479
109	Targeting MYCN in neuroblastoma by BET bromodomain inhibition. *Cancer Discovery*, **2013**, 3, 308-23	24.4	460
108	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. *Nature*, **2016**, 529, 413-417	50.4	363
107	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. *Blood*, **2012**, 120, 2843-52	2.2	298
106	The dTAG system for immediate and target-specific protein degradation. *Nature Chemical Biology*, **2018**, 14, 431-441	11.7	295
105	BET bromodomains mediate transcriptional pause release in heart failure. *Cell*, **2013**, 154, 569-82	56.2	277
104	Small-molecule inhibition of BRDT for male contraception. *Cell*, **2012**, 150, 673-84	56.2	277
103	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. *Nature Medicine*, **2014**, 20, 732-40	50.5	213
102	Acetylation site specificities of lysine deacetylase inhibitors in human cells. *Nature Biotechnology*, **2015**, 33, 415-23	44.5	186
101	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. *Nature Medicine*, **2017**, 23, 1063-1071	50.5	169
100	DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. *Nature Medicine*, **2015**, 21, 335-43	50.5	160
99	An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. *Nature Genetics*, **2016**, 48, 265-72	36.3	152
98	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. *Molecular Cancer Therapeutics*, **2014**, 13, 1142-54	6.1	143

97	Genome-wide localization of small molecules. *Nature Biotechnology*, **2014**, 32, 92-6	44.5	138
96	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. *Nature Chemical Biology*, **2018**, 14, 405-412	11.7	125
95	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. *Nature Medicine*, **2016**, 22, 632-40	50.5	122
94	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. *Journal of Molecular and Cellular Cardiology*, **2013**, 63, 175-9	5.8	118
93	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. *Cancer Cell*, **2018**, 33, 29-43.e7	24.3	113
92	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 13162-13167	11.5	89
91	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. *International Journal of Cancer*, **2015**, 136, 2055-64	7.5	79
90	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. *Blood*, **2015**, 126, 1565-74	2.2	76
89	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. *Journal of Clinical Investigation*, **2018**, 128, 446-462	15.9	72
88	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. *Cancer Discovery*, **2016**, 6, 1006-21	24.4	71
87	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. *ELife*, **2018** , 7,	8.9	70
86	Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. *Chemistry and Biology*, **2013**, 20, 713-25		68
85	Synthetic transcription elongation factors license transcription across repressive chromatin. *Science* , **2017**, 358, 1617-1622	33.3	68
84	Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2020**, 10, 270-287	24.4	68
83	Biased multicomponent reactions to develop novel bromodomain inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 9019-27	8.3	67
82	Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. *ELife*, **2018** , 7,	8.9	62
81	Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. *Circulation Research*, **2019**, 125, 662-677	15.7	56
80	Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. *Cancer Discovery*, **2016**, 6, 1237-1247	24.4	55

79	Chemical genomics reveals histone deacetylases are required for core regulatory transcription. *Nature Communications*, **2019**, 10, 3004	17.4	55
78	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. *Cancer Discovery*, **2016**, 6, 986-1005	24.4	52
77	Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. *EMBO Molecular Medicine*, **2017**, 9, 482-497	12	50
76	Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. *Clinical Cancer Research*, **2015**, 21, 2348-58	12.9	42
75	Relative Binding Free Energy Calculations Applied to Protein Homology Models. *Journal of Chemical Information and Modeling*, **2016**, 56, 2388-2400	6.1	40
74	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. *Oncogene*, **2018**, 37, 2850-2862	9.2	38
73	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. *Cancer Research*, **2016**, 76, 4470-80	10.1	38
72	Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. *Clinical Cancer Research*, **2017**, 23, 430-440	12.9	38
71	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. *Molecular Cell*, **2020**, 78, 1096-1113.e8	17.6	35
70	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). *Pharmaceutical Patent Analyst*, **2015**, 4, 261-84	0.6	34
69	BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. *Cancer Cell*, **2019**, 35, 752-766.e9	24.3	33
68	Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 7785-7795	8.3	32
67	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. *Journal of Medicinal Chemistry*, **2017**, 60, 4805-4817	8.3	31
66	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. *ACS Chemical Biology*, **2018**, 13, 2438-2448	4.9	31
65	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer Cell*, **2018**, 34, 922-938.e7	24.3	31
64	Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor B (NF-B) signaling. *Journal of Biological Chemistry*, **2013**, 288, 36094-105	5.4	30
63	Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2268-2280	5.6	29
62	Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2016**, 1859, 564-71	6	28

61	YAP1-Mediated Suppression of USP31 Enhances NFB Activity to Promote Sarcomagenesis. *Cancer Research*, **2018**, 78, 2705-2720	10.1	27
60	Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. *Nucleic Acids Research*, **2015**, 43, 7790-804	20.1	26
59	High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. *Nature Communications*, **2020**, 11, 3455	17.4	26
58	Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. *Leukemia*, **2019**, 33, 2685-2694	10.7	24
57	HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase. *Science Translational Medicine*, **2017**, 9,	17.5	24
56	YAP1 enhances NF-B-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. *Cell Death and Disease*, **2018**, 9, 1108	9.8	20
55	Structure-guided DOT1L probe optimization by label-free ligand displacement. *ACS Chemical Biology*, **2015**, 10, 667-74	4.9	19
54	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nature Communications*, **2019**, 10, 2400	17.4	18
53	Using Chemical Epigenetics to Target Cancer. *Molecular Cell*, **2020**, 78, 1086-1095	17.6	18
52	HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. *Oncotarget*, **2017**, 8, 80109-80123	3.3	18
51	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. *Journal of Experimental Medicine*, **2018**, 215, 197-216	16.6	16
50	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. *Nature Communications*, **2020**, 11, 2350	17.4	15
49	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. *Haematologica*, **2018**, 103, 939-948	6.6	14
48	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. *Blood*, **2019**, 133, 94-99	2.2	14
47	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. *JCI Insight*, **2020**, 5,	9.9	12
46	BET bromodomain is a novel regulator of TAZ and its activity. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2016**, 1859, 1527-1537	6	12
45	A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma. *Neuro-Oncology*, **2019**, 21, 1150-1163	1	11
44	Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE mice. *International Journal of Cardiology*, **2016**, 223, 428-432	3.2	11

43	Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 T cells ex vivo. *Science Advances*, **2020**, 6, eaba1941	14.3	9
42	Epigenetic CRISPR Screens Identify as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. *Cancer Research*, **2020**, 80, 3556-3567	10.1	8
41	Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors. *Oncotarget*, **2018**, 9, 35408-35421	3.3	8
40	ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. *Molecular Cell* , **2021**, 81, 3604-3622.e10	17.6	8
39	Peptide-Based PROTAC: The Predator of Pathological Proteins. *Cell Chemical Biology*, **2020**, 27, 637-639	8.2	6
38	Development of Dimethylisoxazole-Attached Imidazo[1,2-]pyridines as Potent and Selective CBP/P300 Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 5787-5801	8.3	6
37	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. *Nature Genetics*, **2021**, 53, 881-894	36.3	6
36	EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. *Cancer Discovery*, **2021**,	24.4	5
35	BET bromodomain inhibition suppresses adipogenesis in mice. *Endocrine*, **2020**, 67, 264-267	4	5
34	BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2. *Neuropharmacology*, **2020**, 177, 108255	5.5	5
33	Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions. *Genomics, Proteomics and Bioinformatics*, **2019**, 17, 319-331	6.5	4
32	Author response: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma **2018**,		4
31	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. *Cancer Discovery*, **2020**, 10, 1894-1911	24.4	4
30	Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. *Blood Cancer Discovery*, **2021**, 2, 370-387	7	4
29	Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection. *Journal of Experimental Medicine*, **2021**, 218,	16.6	4
28	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. *Cell Reports*, **2021**, 34, 108870	10.6	3
27	Selective Targeting of Different Bromodomains by Small Molecules. *Cancer Cell*, **2020**, 37, 764-766	24.3	2
26	Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). *Experimental Hematology*, **2019**, 75, 53-63.e11	3.1	2

25	SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells. *Blood*, **2014**, 124, 1566-1566	2.2	2
24	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. *Blood*, **2014**, 124, 535-535	2.2	2
23	Brd4 participates in epigenetic regulation of the extinction of remote auditory fear memory. *Neurobiology of Learning and Memory*, **2021**, 179, 107383	3.1	2
22	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. *Neoplasia*, **2021**, 23, 624-633	6.4	2
21	Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy. *Cancer Research*, **2021**, 81, 6018-6028	10.1	2
20	Inhibition of BET bromodomain improves anemia in APC mice. *Leukemia and Lymphoma*, **2017**, 58, 989-992	2.9	1
19	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. *Blood*, **2019**, 134, 877-877	2.2	1
18	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 3021-3021	2.2	1
17	Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2. *Blood*, **2014**, 124, 778-778	2.2	1
16	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. *Blood*, **2015**, 126, 3784-3784	2.2	1
15	Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins. *Blood*, **2012**, 120, 399-399	2.2	1
14	Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells. *Blood*, **2013**, 122, 2842-2842	2.2	1
13	BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells. *Blood*, **2013**, 122, 485-485	2.2	1
12	Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia. *Blood*, **2013**, 122, 598-598	2.2	1
11	Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. *Leukemia*, **2021**,	10.7	1
10	A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
9	Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative. *Blood*, **2014**, 124, 2158-2158	2.2	
8	Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform. *Blood*, **2014**, 124, 4811-4811	2.2	

7	Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells. *Blood*, **2014**, 124, 918-918	2.2
6	Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells. *Blood*, **2014**, 124, 3534-3534	2.2
5	Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma. *Blood*, **2015**, 126, 589-589	2.2
4	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. *Blood*, **2011**, 118, 1409-1409	2.2
3	BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 672-672	2.2
2	Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD. *Blood*, **2013**, 122, 3821-3821	2.2
1	Dihydropyridine Lactam Analogs Targeting BET Bromodomains.. *ChemMedChem*, **2021**, e202100407	3.7